GleamWall
中文EN

MNPR Monopar Therapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0—————
R&D expense$4.44M$4.77M$3.49M$3.94M$2.59M$1.73M$1.64M$9.92M
SG&A expense$3.03M$1.88M$1.74M$2.21M$1.50M$1.50M$1.58M$1.15M
Operating income-$7.47M-$6.64M-$5.23M-$6.16M-$4.09M-$3.23M-$3.22M-$11.07M
Net income-$6.20M-$5.31M-$3.89M-$5.20M-$3.44M-$2.45M-$2.62M-$10.93M
EPS (basic)-0.72-0.62-0.46—-0.48-0.35-0.38—
EPS (diluted)————————
Balance sheet
Cash & equivalents$52.63M$52.76M$52.54M$61.83M$127.68M$39.50M$39.71M$45.82M
Short-term investments$52.49M$52.61M$52.37M$60.88M$127.50M$39.33M$39.51M$45.53M
Current assets$129.88M$134.76M$137.74M$140.46M$144.09M$53.75M$55.08M$60.29M
Total assets$130.25M$134.98M$137.98M$140.72M$144.20M$53.87M$55.09M$60.29M
Current liabilities$2.98M$4.02M$2.46M$2.74M$2.57M$1.58M—$5.25M
Total liabilities$3.18M$4.12M$2.59M$2.89M$2.64M$1.66M$1.49M$5.25M
Shareholders' equity$127.07M$130.85M$135.39M$137.83M$141.56M$52.20M$53.59M$55.04M
Shares outstanding6.76M6.71M6.70M6.69M6.66M6.13M6.12M6.10M
Cash flow statement
Operating cash flow-$6.17M-$3.25M-$3.47M-$3.37M-$2.09M-$1.08M-$5.66M-$2.00M
Investing cash flow$5.46M$4.12M-$5.58M-$62.19M-$2.13M$1.19M-$325,828-$14.34M
Financing cash flow$586,232-$647,389-$200,203-$384,680$92.39M-$316,845-$115,682$56.14M
Stock-based compensation$2.04M$1.43M$1.69M$1.10M$1.10M$1.28M$1.36M$278,612
Share buybacks———$0———$0

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.